Clinical predictors for efficacy of erenumab for migraine: a Registry for Migraine (REFORM) study.

ABSTRACT: Erenumab has proven effective for migraine prevention; however, a substantial proportion of people with migraine do not benefit from treatment, and among those who do, there is considerable variability in response. This study aimed to identify clinical predictors of therapeutic response to erenumab and evaluate their predictive value in a large cohort of people with migraine. We conducted a single-centre, prospective, longitudinal cohort study of adults with migraine, experiencing ≥4 monthly migraine days. All participants received erenumab 140 mg monthly for 24 weeks and recorded their response in a headache diary with daily entries. A semi-structured interview was conducted at enrolment, and patient-reported outcome measures were collected before and after treatment. Treatment responders

SUBMITTER: Karlsson WK 

PROVIDER: S-EPMC12015094 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature